{
    "guideline_identifier": "PIIS0923753423050743.txt",
    "cancer_focus": {
        "primary_cancer": "Primary Central Nervous System Lymphoma (PCNSL)",
        "related_syndrome_or_condition": [
            "Primary Vitreoretinal Lymphoma (PVRL)",
            "Secondary CNS Lymphoma (SCNSL)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Newly Diagnosed PCNSL",
            "risk_group": "Fit Patients (Suitable for HDC/ASCT)",
            "treatment_plans": [
                {
                    "clinical_context": "Induction therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "MATRix regimen (high-dose methotrexate + high-dose cytarabine + rituximab + thiotepa)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD20",
                            "status": "Positive",
                            "testing_guidance": "IHC on tumor tissue (standard diagnostic panel)"
                        }
                    ],
                    "esmo_evidence_level": "I-A"
                },
                {
                    "clinical_context": "Consolidation therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "High-dose chemotherapy with autologous stem cell transplantation (HDC/ASCT) using thiotepa-based conditioning",
                    "treatment_line": "First-line consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I-A"
                },
                {
                    "clinical_context": "Consolidation for ASCT-ineligible",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Whole-brain radiotherapy (WBRT) at 36-40 Gy",
                    "treatment_line": "First-line consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I-A"
                }
            ]
        },
        {
            "staging_criteria": "Newly Diagnosed PCNSL",
            "risk_group": "Elderly/Unfit for ASCT",
            "treatment_plans": [
                {
                    "clinical_context": "Induction therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "High-dose methotrexate (≥3 g/m²) + rituximab + procarbazine/temozolomide",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD20",
                            "status": "Positive",
                            "testing_guidance": "IHC on tumor tissue"
                        }
                    ],
                    "esmo_evidence_level": "I-A"
                },
                {
                    "clinical_context": "Post-induction management",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Avoid WBRT due to neurotoxicity risk",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I-D"
                },
                {
                    "clinical_context": "Maintenance therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Lenalidomide or temozolomide maintenance",
                    "treatment_line": "First-line maintenance",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV-C"
                }
            ]
        },
        {
            "staging_criteria": "Newly Diagnosed PCNSL",
            "risk_group": "Unfit for HD-MTX",
            "treatment_plans": [
                {
                    "clinical_context": "Palliative therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Palliative WBRT (30-36 Gy), corticosteroids, oral alkylators, or novel agents (ibrutinib)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III-B, V-C"
                }
            ]
        },
        {
            "staging_criteria": "PVRL",
            "risk_group": "First-Line",
            "treatment_plans": [
                {
                    "clinical_context": "Systemic therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "High-dose methotrexate-based regimens",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD20",
                            "status": "Positive",
                            "testing_guidance": "IHC on tumor tissue"
                        }
                    ],
                    "esmo_evidence_level": "IV-C"
                },
                {
                    "clinical_context": "Local ocular therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Intravitreal methotrexate or rituximab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV-B"
                }
            ]
        },
        {
            "staging_criteria": "PVRL",
            "risk_group": "Relapsed/Refractory",
            "treatment_plans": [
                {
                    "clinical_context": "Salvage therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ASCT, ibrutinib, lenalidomide, or temozolomide",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory PCNSL",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Salvage therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "High-dose cytarabine or ifosfamide followed by ASCT or WBRT",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III-B"
                },
                {
                    "clinical_context": "Late relapse",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Rechallenge with high-dose methotrexate",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [
                        {
                            "name": "CD20",
                            "status": "Positive",
                            "testing_guidance": "IHC on tumor tissue"
                        }
                    ],
                    "esmo_evidence_level": "IV-B"
                },
                {
                    "clinical_context": "BTK inhibitor therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Ibrutinib or tirabrutinib",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III-B"
                },
                {
                    "clinical_context": "CAR T-cell therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "CD19-directed CAR T-cell therapy (e.g., tisagenlecleucel)",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [
                        {
                            "name": "CD19",
                            "status": "Positive",
                            "testing_guidance": "IHC or flow cytometry on tumor tissue/CSF"
                        }
                    ],
                    "esmo_evidence_level": "V-C"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "MYD88 L265P and IL-10 serve as diagnostic biomarkers in CSF/vitreous fluid. CD20 expression enables rituximab-based immunotherapy. CD19 positivity is required for CD19-targeted therapies including CAR T-cell treatment."
    }
}